Moreover, the firm predicted that its top line would increase at least 5% this year excluding currency changes, while it provided 2025 free cash flow guidance of $13.5 billion, versus analysts’ ...
VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S.